Anti-thrombotic therapy in patients with AFib undergoing percutaneous coronary intervention (PCI) is an important consideration. Christopher Cannon, MD, Professor of Medicine at Harvard Medical School, talks with DocWire News on the topic.

Dr. Cannon talks about  how dual antithrombotic therapy combined with the blood thinner dabigatran and a P2Y inhibitor could potentially be a more effective (and less risky) alternative to standard care in these patients. Although the standard of care for AFib patients who undergo PCI has been triple antithrombotic therapy with warfarin, plus two antiplatelet agents, that course of action may be risky and result in significant bleeding events.